Nano-based carriers for pulmonary drug delivery: A review on the available drug delivery applications and toxicity issues
In the last decade, nanocarriers have been widely used to target specific organs and
disorders of any kind. Nonetheless, the commercialization of nanocarriers for many …
disorders of any kind. Nonetheless, the commercialization of nanocarriers for many …
Chronic Obstructive Lung Disease: Treatment Guidelines and Recommendations for Referral and Multidisciplinary Continuity of Care
J De Miguel-Díez, A Fernández-Villar… - Journal of Clinical …, 2024 - mdpi.com
Chronic Obstructive Pulmonary Disease (COPD) constitutes a major public health problem,
and it is anticipated that its prevalence will continue to increase in the future. Its progressive …
and it is anticipated that its prevalence will continue to increase in the future. Its progressive …
[HTML][HTML] Effectiveness of roflumilast in treating chronic obstructive pulmonary disease: A systematic review and meta-analysis
Background Chronic obstructive pulmonary disease (COPD) is a chronic airflow obstructive
condition. The mainstay of treatment is to avoid exacerbation and manage the symptoms …
condition. The mainstay of treatment is to avoid exacerbation and manage the symptoms …
Prescription Pathways from Initial Medication Use to Triple Therapy in Older COPD Patients: a Real-World Population Study
Background and objective Triple therapy with an inhaled corticosteroid (ICS), a long-acting
β2-agonist bronchodilator (LABA) and a long-acting muscarinic antagonist (LAMA) is …
β2-agonist bronchodilator (LABA) and a long-acting muscarinic antagonist (LAMA) is …
[HTML][HTML] Bronchoscopic lung volume reduction: status quo
M Zantah, AJ Gangemi, GJ Criner - Annals of translational …, 2020 - ncbi.nlm.nih.gov
Emphysema is associated with irreversible loss of lung compliance leading to gas trapping
and hyperinflation. Surgical lung volume reduction has proven to improve lung function …
and hyperinflation. Surgical lung volume reduction has proven to improve lung function …
Development and validation of LC-MS/MS methods for the quantification of 101BHG-D01, a novel, long-acting and selective muscarinic receptor antagonist, and its …
H Gao, M Cheng, H Liu, L Ding - Journal of Pharmaceutical and Biomedical …, 2023 - Elsevier
Abstract 101BHG-D01 is a novel, long-acting and selective muscarinic receptor antagonist
for the treatment of chronic obstructive pulmonary disease (COPD) and rhinorrhea in rhinitis …
for the treatment of chronic obstructive pulmonary disease (COPD) and rhinorrhea in rhinitis …